Program
pamlectabart tismanitin
Its studies are mostly in Multiple Myeloma, led by 2 companies.
Furthest: phase 2, since Apr 23, 20212 company-led studies, 2 open or runningNext primary completion: Mar 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Heidelberg Pharma | 11 open or running | phase 2since Apr 23, 2021 | Apr 23, 2021 | Mar 2028phase 2 · NCT04879043 |
| Huadong Medicine | 11 open or running | phase 1since Mar 3, 2026 | Mar 3, 2026 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 23, 2021First study: phase 2 study in Multiple MyelomaNew to Heidelberg PharmaHeidelberg Pharma · NCT04879043 · 78 planned · United States, Germany, Hungary and more
- Mar 3, 2026Huadong Medicine’s first study: phase 1 study in Neoplasms, Plasma CellNew to Huadong MedicineHuadong Medicine · NCT07529782 · 15 planned · China
Ahead
- Mar 2028Primary completion: phase 2 study in Multiple MyelomaHeidelberg Pharma · NCT04879043
TargetBeta
TNFRSF17 →read by rule
“An antibody-drug conjugate (ADC) consisting of pamlectabart, a humanized immunoglobulin G1-kappa monoclonal antibody against the tumor-associated antigen (TAA) B-cell maturation antigen (BCMA, TNFRSF17) ”NCIt, by rule
Other programs on TNFRSF17
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| elranatamabrule | Pfizer | phase 4 | 15 |
| linvoseltamabrule | Regeneron Pharmaceuticals | phase 4 | 13 |
| teclistamabrule | Johnson & Johnson | phase 4 | 11 |
| belantamab mafodotinrule | GlaxoSmithKline | phase 3 | 25 |
| Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F | AstraZeneca | phase 3 | 12 |
| etentamig | AbbVie | phase 3 | 11 |
| ramantamig | Johnson & Johnson | phase 3 | 8 |
| anitocabtagene autoleucelrule | Gilead Sciences | phase 3 | 6 |
| equecabtagene autoleucelrule | nanjing-iaso-biotechnology-co-ltd | phase 3 | 5 |
| Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934 | Sino Biopharmaceutical | phase 3 | 4 |
| GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003rule | Innovent Biologics | phase 3 | 4 |
| Evarucabgene Autoleucelrule | nexcella-inc | phase 3 | 2 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07529782Neoplasms, Plasma Cell · China | 1 | Recruiting | Huadong Medicine | Jun 30, 2026 | 15 |
| NCT04879043Multiple Myeloma · United States, Germany, Hungary and more | 2 | Recruiting | Heidelberg Pharma | Mar 2028 | 78 |
How it is read
Names in the registry
- “HDP-101”, 2 entries
Conditions, from the studies’ own filings
- Multiple Myeloma, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.